Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
Fall brings us cooler weather, colorful trees and harvest fairs and festivals. But it also brings us the beginning of flu season. Since the flu season lasts from about October to May – and peaks between December to February – you need to do all you can to protect yourself against the flu, especially if you have asthma.
But many people avoid the flu vaccine because they have some concerns about the safety of the vaccine or need for the vaccine.
Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study’s primary objective, and showed superior efficacy in the primary endpoint of time to improvement of influenza symptoms versus placebo.
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .